Clinical trials
CMV Infection clinical trials
Below are recruiting cmv infection clinical trials, each written for real people, not researchers. We’re tracking 39 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03266640RecruitingPhase 2
CMV cell therapy for difficult-to-treat viral infection
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT07079735RecruitingPhase 2/Phase 3
Preventing CMV after heart transplant
This trial compares two antiviral drugs, valganciclovir and letermovir, to see which works better at preventing CMV infection after a heart transplant. If you've had a heart transplant and haven't started preventive treatment yet, this study may be for you.
New York, New YorkAges 18–99 - NCT04013802RecruitingPhase 1
Multivirus T-cell treatment for EBV, CMV, adenovirus, and BK after transplant
This Phase 1 study tests an “off-the-shelf” type of immune cell therapy made to attack several viruses (EBV, CMV, adenovirus, and BK, and possibly JC) in people who had an allogeneic stem cell transplant and still have ongoing viral infection. It may help your body control the virus when standard treatments have not worked or you cannot tolerate them.
Houston, TexasAges Any age - NCT07235683RecruitingPhase 4
Stronger CMV treatment for lung transplant recipients
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
Toronto, OntarioAges 18 years+ - NCT04439916Recruiting
Preventing CMV after lung transplant in special donor/recipient pairs
This study looks at how to prevent and monitor a virus called CMV after a lung transplant. It is for adults who are not carrying CMV themselves, but who receive lungs from donors who are CMV-positive, and it may help tailor safer follow-up care after transplant.
Edmonton, AlbertaAges 18 years+ - NCT06066957RecruitingPhase 2
Oral letermovir to prevent CMV after heart or lung transplant
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07688759Recruiting
Immune response measurement for first CMV after transplant
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
Suzhou, JiangsuAges 18 years+ - NCT06407232RecruitingPhase 3
Letermovir for CMV after kidney or pancreas transplant
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
Madison, WisconsinAges 18 years+ - NCT07569653RecruitingPhase 4
CMV Prevention After Stem Cell Transplant Using Blood Tests
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03354728RecruitingPhase 1/Phase 2
Vaccine trial for children with CMV after stem cell transplant
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
Duarte, CaliforniaAges 1–21 - NCT07013370Recruiting
Preventing CMV in Children After Stem Cell Transplant
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
TriesteAges 1 month–18 years - NCT04030676Recruiting
Test for CMV reactivation risk during ulcerative colitis flare
This study checks whether a blood test (QuantiFERON-CMV, related to prior CMV infection) can predict if CMV might reactivate during a severe ulcerative colitis flare. It may help doctors spot people at higher risk and potentially guide monitoring and treatment during hospitalization.
LyonAges 18 years+ - NCT01011712Recruiting
Study immune causes of severe viral infections
This study looks at why some people have severe or unusual viral infections, even when they do not have a known immune problem. It collects blood and tissue samples to better understand possible inherited immune issues and may help future diagnosis and treatment.
Bethesda, MarylandAges 2–100 - NCT07294547Recruiting
Comparing two antivirals for kidney transplant patients
This trial compares two antiviral drugs, valacyclovir and valganciclovir, to see if valacyclovir works as well as valganciclovir for preventing CMV and EBV infections after a kidney transplant.
TaipeiAges 3 years+ - NCT06058858Recruiting
CMV reactivation after CAR-T cell therapy for leukemia or lymphoma
This study looks at how often a common virus called CMV reactivates—meaning it becomes active again—in patients who receive CAR-T cell treatment for leukemia or lymphoma. It aims to understand the risks and help doctors better manage care.
ParisAges 1–100
Hear when a new CMV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cmv infection?
- Yes. Clin2 currently lists 39 recruiting cmv infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cmv infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cmv infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.